Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT05796388·Not applicable·INTERVENTIONAL

A Study of Virtual Reality and Linaclotide for IBS-C

LinaclotideOtherRecruiting

Status

Recruiting

Phase

Not applicable

Enrollment

65

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (placebo) VR therapy.

Full detailed description

The primary aim of this study will be to assess the benefits of disease-targeted VR combined with linaclotide, compared to sham VR combined with linaclotide, in patients with IBS-C as defined by Rome IV criteria. The investigators hypothesize that compared to patients receiving sham VR and linaclotide, IBS-C patients receiving combination therapy with active VR and linaclotide will achieve statistically significant and clinically meaningful improvements in disease-targeted health-related quality of life while demonstrating improvements in global IBS symptoms, including abdominal pain. Aims 1. Evaluate changes in quality of life using the validated IBS-QoL (primary outcome); 2. Evaluate global improvement in IBS symptoms using the validated IBS-SSS; 3. Assess global improvement in IBS symptoms using the validated Abdominal Scoring system (11); 4. Evaluate improvement in abdominal pain using a numerical rating system (NRS); 5. Assess improvement in constipation using the Bristol Stool Form Scale (BSFS); 6. Evaluate response to bloating using the validated Mayo bloating questionnaire (12); 7. Assess response to coexisting psychological distress using the validated HADs questionnaire; 8. Evaluate changes in work productivity using the validated WPAI.

Interventions

Treatment arms and agents.

DEVICE

Virtual Reality

Both groups will receive standard of care linaclotide 290 mcg.

Timeline

From registration to results.

  1. First posted

    Apr 3, 2023

  2. Study start

    May 31, 2024

  3. Primary completion

    Oct 2026

  4. Study completion

    Oct 2026

  5. Results posted

    Not reported

  6. Registry updated

    Jul 29, 2026

Outcomes

What the study measures.

Primary outcomes

Changes in IBS symptoms

Time frame · End of study week 8 compared to baseline

Measure global changes in IBS symptoms using the validated IBS severity scoring system (IBS-SSS) at week 8 compared to baseline, for patients treated with a combination of linaclotide and immersive VR and compare to those treated with linaclotide and sham VR therapy. IBS-SSS is a composite score of abdominal pain, number of days with abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life (QoL). Each measure is rated from 0 to 100, with total scores ranging from 0 to 500. \< 175 for mild IBS, 175-300 for moderate IBS, and \> 300 for severe IBS.

Secondary outcomes

Measure change in quality of life, using the validated IBS-QoL

Time frame · Week 8

Irritable Bowel Syndrome-Quality of Life Measure (IBS-QOL) The individual responses to the 34 items are summed and averaged for a total score and then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS specific quality of life.

Measure changes in abdominal pain using the NRS

Time frame · Week 8

The Abdominal Pain Numeric Rating Scale (NRS) patients are asked to circle the number between 0 and 10, 0 and 20 or 0 and 100 that fits best to their pain intensity. Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible'.

Measure changes in bloating using the Mayo bloating questionnaire

Time frame · week 8

A 40-item questionnaire to understand the daily impact of symptoms of bloating and distension

Measure changes in psychological distress using the HADs questionnaire;

Time frame · week 8

The Hospital Anxiety and Depression Scale (HADs) consists of 14 items and consists of two subscales: anxiety and depression. Each item is rated on a four-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represents 'borderline' and 0-7 'normal'

Measure changes in work productivity using the validated WPAI.

Time frame · Week 8

The Work Productivity and Activity Impairment (WPAI) questionnaire consists of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
70 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Adult men and women (18-70) who meet Rome IV criteria for IBS-C. * Patients will be required to score below 65 points on the IBS Quality of Life (IBS-QOL) instrument, indicating a score consistent with at least moderate HRQOL (Health-related quality of life) impairment. Exclusion Criteria: * Patients will be excluded from the study if they have a comorbid disorder that may confound the diagnosis of IBS, including celiac disease, inflammatory bowel disease, autoimmune disorders that affect the GI system, history of bowel resection, HIV/AIDS, diabetes with HgA1c \>7.0, neuroendocrine tumors, microscopic colitis, lactase deficiency, eosinophilic bowel disease, acute intermittent porphyria, or any other condition that a licensed physician believes can mimic IBS symptoms and undermine diagnostic certitude. * Patients with severe depression, defined as a score equal to or greater than two standard deviations (SDs) on the NIH PROMIS depression scale, or those with suicidal ideations, will also be excluded and provided with standard resources to support their mental health and referred back to their primary care provider, a member of the study team will follow up with the PCP to ensure the communication was received. * Patients using regular doses of opioid medications will also be excluded given the often-severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia. * Patients will also be excluded from the study if they do not meet Rome IV criteria for IBS-C, * have a known seizure disorder, * if symptoms are thought to represent an organic disorder, * if they have had prior surgery to the colon, * if symptoms represent a known pelvic floor disorder, * if the patient is abusing alcohol, * or if the patient cannot actively participate in the study for any other reason (e.g., inability to understand English as the VR program is in English only). * Patients previously treated with linaclotide who reported side effects, * those currently on linaclotide (any dose), * and those who did not note an improvement in IBS-C symptoms in the past while on linaclotide will also be excluded.

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Mayo Clinic Florida

Jacksonville, Florida, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsLinaclotide trial dashboard →